Did you hear about namilumab? I’ve looked at the abstracts of the ACR
2017 Annual Meeting and the EULAR 2017 Annual Meeting, but nothing had been
discussed about namilumab at these two big meetings.
Namilumab is an investigational drug. Namilumab, also called MT203, is
a human monoclonal antibody (class IgG1 kappa) and targets GM-CSF. Current
phase 2 research covers not only rheumatoid arthritis (RA) but also psoriatic
arthritis (PsA) [1,2].
T.W. Huizinga and colleagues published a study in 2017 [3]: “Phase 1b
randomized, double-blind study of namilumab, an anti-granulocyte macrophage
colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid
arthritis.” Conclusions: “Subcutaneous
namilumab was generally well tolerated. Although namilumab demonstrated
preliminary evidence of efficacy, patient numbers were small; phase 2 studies
are ongoing.” The study shows that the drug is still under investigation.
But I have my problems to believe in drug against RA targeting GM-CSF (Granulocyte
Macrophage-Colony Stimulating Factor) [4]. Mavrilimumab showed up with one (!)
study at the ACR 2017 Annual Meeting with a look at safety data (pulmonary
function). MOR103 has been hibernating after 2015 [5,6].
Even if Professor Burmester keeps up being enthusiastic about a drug targeting
GM-CSF, I don’t see that drug appearing on the horizon of the rheumatologic
globe.
Links:
.
No comments:
Post a Comment